It is currently Sun May 28, 2017 11:31 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Apolioprotein E

I'm happy about anything that mentions neuroprotection..

: J Pharmacol Exp Ther. 2006 Jun 1; Links

Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.

Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP.

Division of Neurology, Department of Medicine, Duke University Medical Center.

Apolipoprotein E (apoE), well known to play a role in lipid transport and ...
Read more : Apolioprotein E | Views : 1418 | Replies : 0


Tovaxin anyone???

Hi everyone

Bromley had said that there was going to be a "poster presentation at the 2006 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) at the San Francisco Marriott on June 3, 2006." That would be today :) . Does annyone have any info on that or is it too early for that?? What can I say, I am anxious. I am ...
Read more : Tovaxin anyone??? | Views : 3807 | Replies : 9


BHT 3009 research

Read more : BHT 3009 research | Views : 1907 | Replies : 1


Oral fumurate research

Read more : Oral fumurate research | Views : 2145 | Replies : 5


TGN1412

Parexel Drug Trial Had Shortfalls, U.K. Investigation Says

Parexel International Corp., which ran a clinical trial that left six men with multiple organ failure earlier this year, didn't have a doctor with adequate training and experience screening the patients, the U.K. health regulator said.

Parexel, based in Waltham, Massachusetts, failed to ensure that closely held German biotechnology company TeGenero AG, which developed the medicine, had proper insurance to cover the volunteers, the London-based Medicines ...
Read more : TGN1412 | Views : 1517 | Replies : 0


Synta

Dignan,

Trials not for MS, but something to keep in mind.

Ian


Synta launches human trials for anti-inflammatory drug

Synta Pharmaceuticals Corp. has launched two new midstage human clinical trials to test an anti-inflammatory drug.
The Lexington, Mass.-based private company said it had began dosing patients in two separate Phase II trials regarding the compound apilimod mesylate. One trial will focus on rheumatoid arthritis and the other will target common variable immunodeficiency, a condition ...
Read more : Synta | Views : 1472 | Replies : 0


Serum

Dignan,

I think the following can be moved from Phase I to Phase II.

Ian


Cambrex to Produce Serum for Trial

Cambrex to Make Serum for Merrimack Pharmaceuticals Autoimmune Disease Study.

Cambrex Corp. said Tuesday one of its subsidiaries will produce a serum for a Merrimack Pharmaceuticals clinical study on autoimmune disease treatments.

The subsidiary, Cambrex Bio Science Hopkinton Inc., will produce trial quantities of Merrimack's lead drug candidate, MM-093, for the Phase II ...
Read more : Serum | Views : 1727 | Replies : 1


Bone Marrow Transplantation

The following appeared on the Canada MS Society 'Ask an Expert' section. The answer was given by Dr Mark Freedman who is oversseing the project. It's good to see that those who have been througt it have not seen a recurrence of their MS and some have seen improvements.

Ian

Q :

A few months ago I saw a program on W-5 about MS patients who were undergoing bone marrow transplantation. Can you tell me ...
Read more : Bone Marrow Transplantation | Views : 1668 | Replies : 1


Allon drugs

Scientific Paper Confirms Mechanism of Allon's Drugs

Allon Therapeutics Inc., The Neuro Protection Company(TM), today announced that results of a preclinical study published in the Journal of Molecular Neuroscience demonstrate that the cellular mechanism that gives neuroprotective properties to its clinical-stage products also occurs in the Company's pipeline of preclinical-stage product candidates.
Dr. Illana Gozes, Chief Scientific Officer of Allon and the corresponding author for the study, said the neuroprotective activity of the Company's ...
Read more : Allon drugs | Views : 1744 | Replies : 0


p75NTR

Mentions other brain disease, so I'm assuming MS included.

The really interesting bit is:

"In further tests, the research team discovered that the compounds can also inhibit the death of oligodendrocytes, the cells in the central nervous system that form myelin, the insulating sheath surrounding nerve cells.

Normally, oligodendrocytes die when exposed to proneurotrophins – precursor forms of neurotrophins that have been implicated as agents of tissue damage in multiple sclerosis, spinal cord injury and ...
Read more : p75NTR | Views : 1573 | Replies : 0


 

Login  •  Register


Statistics

Total posts 238249 • Total topics 25918 • Total members 17179


Contact us | Terms of Service